Keytruda
Pembrolizumab
Why Keytruda Costs $18,176.00 Per Claim
Keytruda (Pembrolizumab) is used to treat cancer. According to CMS Medicare Part D spending data, the program spent $7.2B on this drug, covering 82,000 beneficiaries across 398,000 claims.
This drug is currently protected by patents expiring Jun 28, 2028. Until patent protection ends, no generic version can enter the market, which limits price competition. Once generics become available, the price typically drops 80-95%.
Spending on Keytruda increased by +28.6% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Keytruda (Pembrolizumab) costs an average of $18,176.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $88,220.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
No, Keytruda is currently brand-only. Patent protection expires Jun 28, 2028, after which generic versions may enter the market.
Medicare Part D spent $7.2B on Keytruda, covering 82,000 beneficiaries across 398,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Check manufacturer patient assistance programs for potential savings. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.